Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FIBROSIS

Financiado

Fibroproliferative Invasive Fibroblasts in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a relentlessly progressive, lethal, lung disease with a uniquely poor prognosis. Patients typically die within 2-5years of diagnosis and IPF’s European incidence is increasing while effective... ver más

02/09/2021

NUID UCD

266K€

Presupuesto del proyecto: 266K€

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-09-02

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100% 100%

4 Participantes

NUID UCD

266.06K€ | Lider

ROTULOS AYLLON, S.A.

286.68K€ | Participante

CEDARS-SINAI MEDICAL CENTER

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TOPFIBRO Targeting OGG1 in Idiopathic Pulmonary Fibrosis 2M€ Cerrado

PID2020-117888RB-I00 REGULACION DE LA MUERTE CELULAR EN LOS FIBROBLASTOS INDUCIDA... 114K€ Cerrado

SAF2017-89908-R ENTENDIENDO EL PAPEL DE LAS CELULAS MADRE DE PULMON EN LA RE... 171K€ Cerrado

SAF2009-13243 DETERMINANTES MECANICOS DE LA FIBROGENESIS PULMONAR ESTUDIAD... 109K€ Cerrado

CPP2021-008747 Investigación del potencial de nuevas moléculas para el trat... 499K€ Cerrado

IJCI-2016-30254 New approaches to reverse cardiac and pulmonary fibrosis 64K€ Cerrado

Duración del proyecto: 40 meses Fecha Inicio: 2018-04-09
Fecha Fin: 2021-09-02

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 266K€

Descripción del proyecto Idiopathic Pulmonary Fibrosis (IPF) is a relentlessly progressive, lethal, lung disease with a uniquely poor prognosis. Patients typically die within 2-5years of diagnosis and IPF’s European incidence is increasing while effective therapies for improving survival remain elusive. IPF is a disease in which the normal wound healing responses are dysregulated leading to fibrosis and loss of gas-exchange regions in the lung rather than restoration of normal lung structure and function. Recently discovered invasive fibroblasts are believed to be central to the progressive fibrogenesis observed in IPF by contributing to an accumulation of fibroblasts in the injured lung and augmenting the destruction of normal alveolar structure. However the source of these invasive fibroblasts and what makes them so uniquely pathogenic is unknown. On this project I will work with Prof. Paul Noble, Cedars-Sinai Medical Centre, USA, one of the world’s leading IPF researchers and Ireland’s leading respiratory researcher Prof. Paul McLoughlin, University College Dublin, Ireland. The objectives of this project are to investigate: (1) the phenotype and behaviour of the invasive fibroblast from human IPF donors in vitro; (2) delineate the molecular pathways that make invasive human IPF fibroblasts uniquely pathogenic using state-of-the-art single cell RNA-sequencing; (3) determine the source of invasive fibroblast accumulation in the IPF lung using the most advanced lineage tracing methods available in a cutting-edge genetically modified mouse model. This interdisciplinary proposal will merge skills I have acquired with the latest technologies across multiple disciplines in world leading international institutions to explore the complex molecular basis of IPF. The results of this proposal will generate significant impact in the IPF field and will be directly applicable to the specific challenge highlighted in the H2020 Work Programme: Diagnostic characterisation of rare diseases.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores